Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Record of Telephone Conversation - May 5, 2009 - Prevnar 13

System Info - 101577  SHONE, DEANNA   06-Aug-2009 16:10:06  SHONEDE


Submission Type: Original Application   Submission ID:  125324/0    Office: OVRR  

Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)

Wyeth Pharmaceuticals Inc.          

Telecon Date/Time:  05-MAY-2009       Initiated by FDA?  Yes
Telephone Number:    

Communication Categorie(s):
Information Request


Telecon Summary:
E-Mail: Comments from Dr. Dragunsky's preliminary review of data submitted to BLA concerning validation of polio neutralization assay and immune response to concomitantly administered polio vaccine among subjects in study 6096A1-3005

FDA Participants:  

Non-FDA Participants:   

Trans-BLA Group: No

Related STNs:  None

Related PMCs:  None

Telecon Body: 


Date:     May 5, 2009
To:       Carmel Devlin, Associate Director
            Global Regulatory Affairs,
            Wyeth Pharmaceuticals Inc.
From:     CDR C. Sweeney, MS, Regulatory Coordinator
CC:       Eugenia Dragunsky,Ph.D.,DVP, Product Reviewer
            Robin Levis, Ph.D., DVP
            Konstantin Chumakov, Ph.D., DVP
            Steven Rubin. Ph.D., DVP
            Julienne Vaillancourt, R.Ph., M.P.H.,Chair
Subject:  CBER Immunoassay Comments on STN 125324

Please respond to the comments below from Dr. Eugenia Dragunsky, based on her preliminary review of data in your BLA concerning validation of the polio neutralization assay and immune response to concomitantly administered poliovirus vaccine among subjects in study 6096A1-3005.

The following comments pertain to the “polio neut sabin” document in section, “Bioanalytical and Analytical Methods for Human Studies”:

1.   In section 2.1.1 (page 7), you state that all three polioviruses met the acceptance criteria for accuracy recovery (b)(4) of GMT’s being within (b)(4)dilution factor of the expected GMT). However, the data in Table 2-indicates that was not achieved for poliovirus type 3. Please clarify.

2.   In section 2.1.3 (pages 7-8), you list tables 2-3 and 2-4. The data in these tables are difficult to interpret. For both tables, please define all column and row headings.  In addition, for Table 2-3, please indicate what the entered data refer to (e.g., numbers 6, 7, 5, 8, 3, 2 etc.)

3.   Please provide data demonstrating specificity of your virus stocks used in these assays. We prefer that this is demonstrated by cross-reactivity studies.

4.   In regard to Table 2-5 in section 2.1.4 (page 9),we note the failures of the poliovirus types 2 and 3 neutralization assays to meet the prescribed acceptance criteria ----(b)(4)----of the samples having expected titers upon dilution). While we agree that the measured titers were very close to the expected titers, the acceptance criteria were nonetheless not met. Please provide additional data in support of adequate assay sensitivity.

5.   In regard to Table 2-7 in section (page 12), please describe the set-up of the table and clarify whether the different dilutions of sera shown in the first column were made from a single high titer serum or five distinct sera.

6.   Please submit the following two documents to the file:

  1. Validation Report of Poliovirus Antibody                                                -----(b)(4)---------- Test, Wyeth Vaccines, Research External Contractor Document. VR-ECD-10012.

  b. Poliovirus Antibody -----------(b)(4)------- Test ((b)(4). Protocol) Wyeth Vaccines Research, External      Contractor Document. VR-ECD-10011.

The following comment pertains to information in the study report body for Clinical Protocol 6096A1-3005-US (section 

7.   In Section 6.5.1 (page 27) we note apparent incorrect reference to use of a (b)(4)neutralization assay in measuring poliovirus antibody responses and apparent incorrect reporting of these antibody responses as IgG titers in Table 9.7 in section (page 70). Please confirm these apparent errors and correct them, as follows:

  1.   In section 6.5.1, it should be indicated that a      -----(b)(4)---------- assay (not a (b)(4) neutralization assay) was performed.

  b.  In table 9.7, section, the presented titers should be described as neutralization titers in footnote “a”.

Contact FDA

(800) 835-4709
(240) 402-8010
Consumer Affairs Branch (CBER)

Division of Communication and Consumer Affairs

Office of Communication, Outreach and Development

Food and Drug Administration

10903 New Hampshire Avenue

Building 71 Room 3103

Silver Spring, MD 20993-0002

Page Last Updated: 04/08/2010
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English